Literature DB >> 19360930

Phenotypic and functional characterization of HIV-1-specific CD4+CD8+ double-positive T cells in early and chronic HIV-1 infection.

Rawleigh Howe1, Stephanie Dillon, Lisa Rogers, Brent Palmer, Samantha MaWhinney, Naomi Blyveis, Rick Schlichtemeier, Michelle D'Souza, Laura Ingoldby, Jeri E F Harwood, Cornelis Rietmeijer, Graham Ray, Elizabeth Connick, Cara C Wilson.   

Abstract

OBJECTIVE: CD4+CD8+ double-positive (DP) T cells represent a poorly characterized population of effector T cells found at low frequencies in the peripheral blood. Virus-specific DP T cells have been identified in HIV-1-infected patients but their origin, relationship to conventional CD4+ and CD8+ single-positive (SP) T cells, and role in disease pathogenesis are unclear.
METHODS: In this study, peripheral blood T cells were analyzed for cytokine production, maturation, and cytolytic marker expression by polychromatic flow cytometry in subjects with both early (n = 27) and chronic (n = 21) HIV-1 infection. RESULTS AND
CONCLUSIONS: HIV-1-specific interferon gamma (IFN-g)-producing DP T cells were identified at a median frequency of 0.48% compared with 1.08% and 0.02% for CD8 and CD4 SP cells, respectively, in response to pooled HIV-1 peptides. HIV-1- specific DP T cells exhibited polyfunctionality with characteristics of both CD4 and CD8 SP T cells, including coproduction of IFN-gamma and IL-2 and expression of cytolytic-associated lysosomal-associated membrane protein. No differences in frequencies of unstimulated DP T cells were observed in early compared with chronic infection. However, chronic infection was associated with higher frequencies of HIV-specific, IFN-gamma-producing DP T cells and higher fractions of effector memory and lysosomal-associated membrane protein expression among these cells, suggesting an effect of cumulative viral antigen burden on DP T-cell function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360930     DOI: 10.1097/qai.0b013e31819aa8c4

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  14 in total

1.  IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques.

Authors:  Rashmi Jalah; Vainav Patel; Viraj Kulkarni; Margherita Rosati; Candido Alicea; Brunda Ganneru; Agneta von Gegerfelt; Wensheng Huang; Yongjun Guan; Kate E Broderick; Niranjan Y Sardesai; Celia LaBranche; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

2.  HIV-1 Nef disrupts intracellular trafficking of major histocompatibility complex class I, CD4, CD8, and CD28 by distinct pathways that share common elements.

Authors:  Jolie A Leonard; Tracy Filzen; Christoph C Carter; Malinda Schaefer; Kathleen L Collins
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

3.  HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.

Authors:  Amie L Meditz; Michelle K Haas; Joy M Folkvord; Kelsey Melander; Russ Young; Martin McCarter; Samantha Mawhinney; Thomas B Campbell; Yolanda Lie; Eoin Coakley; David N Levy; Elizabeth Connick
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

4.  Distinctive Leukocyte Subpopulations According to Organ Type in Cynomolgus Macaques.

Authors:  Jonah S Zitsman; Paula Alonso-Guallart; Christopher Ovanez; Yojiro Kato; Joanna F Rosen; Joshua I Weiner; Raimon Duran-Struuck
Journal:  Comp Med       Date:  2016       Impact factor: 0.982

5.  CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection.

Authors:  Marc A Frahm; Ralph A Picking; JoAnn D Kuruc; Kara S McGee; Cynthia L Gay; Joseph J Eron; Charles B Hicks; Georgia D Tomaras; Guido Ferrari
Journal:  J Immunol       Date:  2012-03-28       Impact factor: 5.422

6.  Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals.

Authors:  Kriangkrai Chawansuntati; Nuntisa Chotirosniramit; Patcharaphan Sugandhavesa; Linda Aurpibul; Sunida Thetket; Natthapol Kosashunhanan; Taweewat Supindham; Oranitcha Kaewthip; Piyathida Sroysuwan; Thira Sirisanthana; Khuanchai Suparatpinyo; Jiraprapa Wipasa
Journal:  Hum Vaccin Immunother       Date:  2015-06-19       Impact factor: 3.452

7.  DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge.

Authors:  Vainav Patel; Rashmi Jalah; Viraj Kulkarni; Antonio Valentin; Margherita Rosati; Candido Alicea; Agneta von Gegerfelt; Wensheng Huang; Yongjun Guan; Brandon F Keele; Julian W Bess; Michael Piatak; Jeffrey D Lifson; William T Williams; Xiaoying Shen; Georgia D Tomaras; Rama R Amara; Harriet L Robinson; Welkin Johnson; Kate E Broderick; Niranjan Y Sardesai; David J Venzon; Vanessa M Hirsch; Barbara K Felber; George N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

8.  Role of novel type I interferon epsilon in viral infection and mucosal immunity.

Authors:  Yang Xi; Stephanie L Day; Ronald J Jackson; Charani Ranasinghe
Journal:  Mucosal Immunol       Date:  2012-05-23       Impact factor: 7.313

9.  Increased CD4+/CD8+ double-positive T cells in chronic Chagasic patients.

Authors:  Nicolas A Giraldo; Natalia I Bolaños; Adriana Cuellar; Fanny Guzman; Ana Maria Uribe; Astrid Bedoya; Natalia Olaya; Zulma M Cucunubá; Nubia Roa; Fernando Rosas; Víctor Velasco; Concepción J Puerta; John M González
Journal:  PLoS Negl Trop Dis       Date:  2011-08-23

10.  Increased CD4+CD8+ Double-Positive T Cell in Patients with Primary Sjögren's Syndrome Correlated with Disease Activity.

Authors:  Sen Wang; Han Shen; Bing Bai; Jia Wu; Junjun Wang
Journal:  J Immunol Res       Date:  2021-05-14       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.